TP53 and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: In the cases of P44-Myo106 and P53-Myo120, with a dystrophinopathy phenotype and reduced expression of dystrophin in muscle biopsy but without pathogenic mutations identified in DMD through the HTS panels used, a deeper study of the DMD gene is required [42].